Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study for a Generic OxyContin®

NORTHVALE, N.J, Jan. 17, 2017, ELTP, (GLOBE NEWSWIRE) Elite Pharmaceuticals, Inc. ( Elite or the “Company ) (OTCBB:ELTP) today reported positive topline results from a pivotal bioequivalence fed study initiated in November 2016.  The topline results indicate that Elite’s generic product is bioequivalent to the branded product, OxyContin® (extended release Oxycodone Hydrochloride). A fasted study was previously conducted in September 2016, also with positive results. The study was a single dose crossover comparative bioavailability study of Oxycodone HCl extended release in
http://bit.ly/2k1Rh2D